Last reviewed · How we verify
rosiglitazone and metformin combination tablet
Rosiglitazone improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), while metformin reduces hepatic glucose production and improves peripheral glucose uptake.
Rosiglitazone improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), while metformin reduces hepatic glucose production and improves peripheral glucose uptake. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | rosiglitazone and metformin combination tablet |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Drug class | Thiazolidinedione + Biguanide combination |
| Target | PPAR-γ (rosiglitazone); Complex I of mitochondrial respiratory chain (metformin) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
This combination tablet pairs a thiazolidinedione (rosiglitazone) that enhances insulin sensitivity in muscle and adipose tissue with a biguanide (metformin) that decreases hepatic gluconeogenesis and improves glucose utilization. Together, they address multiple pathophysiologic defects in type 2 diabetes through complementary mechanisms, reducing both fasting and postprandial hyperglycemia.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Weight gain
- Edema
- Hypoglycemia
- Gastrointestinal disturbance (metformin-related)
- Headache
- Upper respiratory tract infection
Key clinical trials
- Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128) (PHASE3)
- Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052) (PHASE3)
- Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes (PHASE3)
- The Impact of Obesity and Obesity Treatments on Breast Cancer (PHASE1)
- A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone (PHASE3)
- Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients (PHASE3)
- Randomized Controlled Trial of Insulin Versus Tablets for Latent Autoimmune Diabetes in Adults (LADA) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: